Loading organizations...
Insulet has raised $69.0M across 3 funding rounds.
Key people at Insulet.
Insulet has raised $69.0M in total across 3 funding rounds.
Insulet, based in Acton, Massachusetts, develops and manufactures innovative insulin delivery systems, primarily the tubeless, wearable Omnipod system, to simplify diabetes management. The company focuses on user-friendly, automated Pod therapy, including the Omnipod 5 Automated Insulin Delivery System, which aims to eliminate the need for daily injections and address the limitations of traditional, cumbersome insulin pumps. A publicly traded entity since its 2005 IPO, Insulet generates revenue through sales of its Omnipod systems and related products. The company introduced the Omnipod DASH system in 2018 and expanded direct distribution in Europe. Insulet was founded in July 2000 by John Brooks III, Amparo Diaz, and Duane DeSisto. Its business model centers on publicly traded company that generates revenue through sales of its Omnipod insulin delivery systems and related products.
Insulet Corporation (NASDAQ: PODD) is a medical device company headquartered in Acton, Massachusetts, specializing in tubeless insulin delivery systems for people with diabetes.[1][2][3][5][6] It manufactures and sells the Omnipod platform, including the flagship Omnipod 5 Automated Insulin Delivery System—a wearable, waterproof patch-pump that integrates with continuous glucose monitors and smartphones for personalized, hands-free insulin dosing without needles or multiple daily injections.[1][2][3] Serving over 500,000 global customers across 25 countries, Insulet generated $2.1 billion in 2024 revenue and holds the #1 position for prescribed automated insulin delivery (AID) systems in the U.S.[2] The company targets individuals with diabetes (and expanding to other conditions via non-insulin drug delivery), solving the pain points of traditional insulin therapy like injections, fingersticks, and cumbersome pumps by offering simplicity, mobility, and automated control.[1][3][4]
Insulet's growth momentum is strong, fueled by U.S. and international launches of Omnipod 5, organizational restructuring for faster innovation, and expansion into new markets and therapeutic areas.[2][3][5]
Insulet was founded in 2000 by a father determined to liberate his son from the burdens of multiple daily insulin injections, sparking the development of the revolutionary tubeless Omnipod system.[2][5][6][7] This personal mission evolved from early Pod-based innovations into a comprehensive insulin management platform, with pivotal advancements like the Omnipod 5 launch accelerating U.S. commercialization and global adoption.[3] Headquartered outside Boston, the company has grown from a diabetes-focused startup to a market leader, now tailoring its Pod technology for broader subcutaneous drug delivery while maintaining its core purpose.[3][4][5]
Insulet stands out in diabetes management through these key strengths:
Insulet rides the wave of digital health and automated insulin delivery, capitalizing on rising diabetes prevalence (affecting millions globally) and advances in wearable sensors, AI-driven personalization, and smartphone integration.[1][2][3] Timing is ideal amid market shifts toward patient-centric, needle-free therapies that improve adherence and outcomes over traditional methods.[3][4] Favorable forces include regulatory approvals for AID systems, international expansion, and demand for non-invasive devices, positioning Insulet as a leader influencing medtech ecosystems by licensing Pod tech for new drugs and setting benchmarks for simplified chronic disease management.[2][3][5]
Insulet's trajectory points to sustained expansion, with international Omnipod 5 rollouts, Pod platform adaptations for non-insulin therapies, and R&D pushing boundaries in automated delivery.[2][3][5] Trends like AI-enhanced personalization, sustainability mandates, and global diabetes surges will propel growth, potentially amplifying its influence as a medtech innovator simplifying lives—as that father's vision promised over two decades ago.[2][5][6]
Insulet has raised $69.0M in total across 3 funding rounds.
Insulet's investors include Versant Ventures.
Key people at Insulet.
Insulet has raised $69.0M across 3 funding rounds. Most recently, it raised $36.0M Series D in March 2004.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2004 | $36M Series D | — | Versant Ventures | Announced |
| Oct 1, 2002 | $22M Series C | — | Versant Ventures | Announced |
| Aug 1, 2001 | $11M Series B | — | Versant Ventures | Announced |
